Ciprofloxacin oral - GlaxoSmithKline

Drug Profile

Ciprofloxacin oral - GlaxoSmithKline

Alternative Names: GR 37547

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 01 Aug 2017 Phase-I clinical trials in Bacterial infections (In volunteers) in South Africa (PO) (NCT03150082)
  • 10 May 2017 GlaxoSmithKline plans a phase I trial for Bacterial infections (In volunteers) (NCT03150082)
  • 10 May 2017 Preclinical trials in Bacterial infections in United Kingdom (PO) before May 2017 (NCT03150082)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top